[7]. National Institute for Health and Care Excellence.Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia. NICE technological appraisal TA385.NICE, 2016.
[6]. Eur Heart J.2022 Sep 7;43(34):3213-3223. [7]. National Institute for Health and Care Excellence.Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia. NICE technological appraisal TA385.NICE, 2016. 教程,30多篇R教程,以及更多科研教程!
[7]. National Institute for Health and Care Excellence.Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia. NICE technological appraisal TA385.NICE, 2016.
[6]. Eur Heart J.2022 Sep 7;43(34):3213-3223. [7]. National Institute for Health and Care Excellence.Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia. NICE technological appraisal TA385.NICE, 2016. 点击链接:https://www.mediecogroup.com/zhuanlan/course...
2009. Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia. Heart. 95: 584-587.Minhas R, Humphries SE, Qureshi N, Neil HA, Group NGD. Controversies in familial hypercholesterol...
Heterozygous familial hypercholesterolaemia (HeFH) affects 1 in 500 people. This represents some 110000 of the UK population, similar to the number having type 1 diabetes. The great majority are either undetected or have received incorrect advice from a physician with inadequate knowledge of their ...
UK NICE have released guidance on the treatment of familial hypercholesterolaemia, in the first systematic guideline that incorporates clinical and cost effectiveness data for the diagnosis and treatment of the condition. The guideline recommends cascade testing for identifying individuals with the ...
However, the relationships of BMI, WC and metabolic syndrome (MS) with central wave reflections and pulse pressure (PP) amplification have never been investigated. Methods: A cohort of 517 treated hypertensives was studied cross-sectionally as function of BMI, WC and presence of MS, the latter...
NICE guidance for identification and treatment of familial hypercholesterolaemia: Commentary 2.EBSCO_AspHeart
From nice guidance to clinical practice: The challenge of setting up a service for Familial Hypercholesterolaemiadoi:10.1016/j.atherosclerosis.2015.10.041Balasingham, S.Wessex Clinical Genetics, UK;Cazeaux, A.Wessex Clinical Genetics, UK;Watson, M....